November 24, 2016 - By Dolores Ford · 0 Comments
Nov 24 is a positive day so far for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) as the ETF is active during the day after gaining 1.67% to hit $25.51 per share. The exchange traded fund has 147.17M net assets and 3.31% volatility this month.
Over the course of the day 10,832 shares traded hands, as compared to an average volume of 56,240 over the last 30 days for ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO).
The ETF is -21.73% of its 52-Week High and 34.25% of its low, and is currently having ATR of 0.92. This year’s performance is -18.92% while this quarter’s performance is 0.47%.
The ETF’s YTD performance is -31.27%, the 1 year is -26.57% and the 3 year is NaN%.
The ETF’s average P/E ratio is 16.31, the price to book is 1.76, the price to sales is 4.13 and the price to cashflow is 8.49. It was started on 12/31/2014. The fund’s top holdings are: Endo International plc – Ordina for 4.72% of assets, Neurocrine Biosciences Inc. for 4.29%, Ionis Pharmaceuticals Inc. for 3.55%, Intercept Pharmaceuticals Inc. for 3.46%, Akorn Inc. for 3.41%, Catalent Inc. Common Stock for 3.22%, ACADIA Pharmaceuticals Inc. for 3.16%, Galapagos NV – American Deposit for 3.16%, Horizon Pharma plc for 3.04%, Juno Therapeutics Inc. for 2.91%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as yield.
More notable recent ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on March 01, 2015, also Zacks.com with their article: “ALPS Puts Twist on Biotech Investing with Medical Breakthrough ETF” published on January 14, 2015, Businesswire.com published: “â€œALPS Medical Breakthroughs ETFâ€ Looks to Capitalize on New Era for Drug Companies” on December 31, 2014. More interesting news about ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) were released by: Seekingalpha.com and their article: “SBIO: A Safe Play In Biotechnology?” published on June 10, 2015 as well as Nasdaq.com‘s news article titled: “The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P …” with publication date: February 02, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford